The estimated Net Worth of Antoine Papiernik is at least $316 Milhão dollars as of 5 July 2023. Mr. Papiernik owns over 17,381 units of Shockwave Medical stock worth over $7,586,105 and over the last 6 years he sold SWAV stock worth over $308,447,846. In addition, he makes $185,253 as Independent Director at Shockwave Medical.
Antoine has made over 32 trades of the Shockwave Medical stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 17,381 units of SWAV stock worth $295,477 on 5 July 2023.
The largest trade he's ever made was selling 650,000 units of Shockwave Medical stock on 4 September 2019 worth over $22,327,500. On average, Antoine trades about 101,233 units every 35 days since 2019. As of 5 July 2023 he still owns at least 22,662 units of Shockwave Medical stock.
You can see the complete history of Mr. Papiernik stock trades at the bottom of the page.
Antoine Papiernik serves as Independent Director of the Company. Mr. Papiernik has been Managing Partner of Sofinnova Partners since 1997. Mr. Papiernik has been an initial investor and a board member in public companies, including ProQr Therapeutics N.V. and Mainstay Medical International plc. Mr. Papiernik is also a board member of private companies MedDay Pharmaceuticals, MD Start, Reflexion Medical, Gecko Biomedical, SafeHeal, Highlife and Rgenix. Mr. Papiernik served on the boards of EOS (Ethical Oncology Science S.p.A., CoAxia, Lectus Therapeutics Ltd, Entourage Medical Technologies, Inc., Corwave SA, Auris Medical Holding and Impatients. Mr. Papiernik previously was an initial investor and a board member of the following companies, Actelion Pharmaceuticals Ltd. (“Actelion”), NovusPharma S.p.A. (sold to Cell Therapeutics, Inc.), Movetis NV (sold to Shire Plc), Pixium Vision SA and Stentys S, which went public respectively on the Zürich stock exchange, Nasdaq, the Stockholm stock exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange and the EuroNext Paris. He was also a board member for Cotherix Inc. (initially Nasdaq listed, then sold to Actelion), CoreValve (sold to Medtronic plc), Fovea Pharmaceuticals (sold to Sanofi-Aventis S.A.) and ReCor Medical, Inc. (sold to Otsuka Pharmaceutical Co., Ltd.). Mr. Papiernik received his M.B.A. from the Wharton School of Business, University of Pennsylvania and his B.S. from Institut Etudes Economiques Commerciales.
As the Independent Director of Shockwave Medical, the total compensation of Antoine Papiernik at Shockwave Medical is $185,253. There are 8 executives at Shockwave Medical getting paid more, with Douglas Godshall having the highest compensation of $2,208,320.
Antoine Papiernik is 53, he's been the Independent Director of Shockwave Medical since 2019. There are 10 older and 4 younger executives at Shockwave Medical. The oldest executive at Shockwave Medical Inc. is John M. Adams, 74, who is the Co-Founder and Technical Advisor.
Antoine's mailing address filed with the SEC is C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA, CA, 95054.
Over the last 6 years, insiders at Shockwave Medical have traded over $488,603,927 worth of Shockwave Medical stock and bought 30,000 units worth $510,000 . The most active insiders traders include James E Deerfield Mgmt L.P...., Antoine Papiernik, eCapital Vii Fcpr Sofinnova. On average, Shockwave Medical executives and independent directors trade stock every 8 days with the average trade being worth of $10,693,924. The most recent stock trade was executed by Trinh Phung on 17 May 2024, trading 19,763 units of SWAV stock currently worth $121,740.
shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen
Shockwave Medical executives and other stock owners filed with the SEC include: